Based on baseline tissue NGS analysis alone, patterns seen in patients with FGFR2 fusion-positive cholangiocarcinoma in FIGHT-202 were recapitulated here across multiple histologies harboring a variety of FGFR1–FGFR3 fusions and mutations. This evidence concerns the gene FGFR2 and cholangiocarcinoma.